{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:00:34Z","timestamp":1790949634811,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background\/Objectives: Next-generation drugs, such as JAK inhibitors and biologics, have proved to be very effective treatment choices in several autoimmune and autoinflammatory skin disorders. However, these drugs are not without risk. Due to their immune-modulating properties, these drugs may pose a risk of infection, which could vary between drug target, disorder type and pathogen. Our goal was to determine infection risk and how it may vary by drug target, pathogen and skin disorder, namely psoriasis, atopic dermatitis, alopecia areata, vitiligo and hidradenitis suppurativa. Methods: We performed a systematic search and meta-analysis where we extracted the rates of different infections from the adverse events of each trial that were found and met our inclusion criteria. Results: We found significant associations in psoriasis and atopic dermatitis where infection risk varied by drug, skin condition and pathogen type. We specifically found that there was an increased risk of viral infection for patients with atopic dermatitis with both JAK inhibitors and biologics. We also found an increased risk of fungal infections in psoriasis patients receiving targeted therapies. Lastly, we observed a decreased risk of bacterial infections in atopic dermatitis with dupilumab specifically. Additionally, there was a significantly higher incidence of herpes simplex infections in atopic dermatitis patients with target-selective JAK inhibitors, while no increased risk was observed with herpes zoster. Conclusions: There is a varied risk with these next-generation medications that needs to be considered when determining treatment regime.<\/jats:p>","DOI":"10.3390\/medicina61112053","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:58:42Z","timestamp":1763459922000},"page":"2053","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Infection Risk in Dermatology Patients Receiving Next-Generation Medication: A Meta-Analysis of JAK Inhibitors and Biologics"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Mediprobe Research Inc., London, ON N5X 2P1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Susmita","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc., London, ON N5X 2P1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-7254","authenticated-orcid":false,"given":"Vasiliki","family":"Economopoulos","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc., London, ON N5X 2P1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000539424","article-title":"Alopecia Areata Is Associated with Posttraumatic Stress Disorder and Alcohol Use in a Case-Control Study of 4785 Patients","volume":"10","author":"Curtis","year":"2024","journal-title":"Skin. Appendage Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/09546634.2019.1708854","article-title":"Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials","volume":"32","author":"Feldman","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tsai, Y.C., Hung, C.Y., and Tsai, T.F. (2023). Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051351"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jdv.20211","article-title":"Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort","volume":"39","author":"Clemmesen","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2500\/aap.2018.39.4175","article-title":"The burden of atopic dermatitis","volume":"39","author":"Reed","year":"2018","journal-title":"Allergy Asthma Proc."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Benton, S., Farah, R., and Hordinsky, M. (2023). Systemic Immunotherapies, Elsevier Inc.. [1st ed.].","DOI":"10.1016\/B978-0-323-82921-2.00019-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40257-016-0220-6","article-title":"Adalimumab: A Review in Hidradenitis Suppurativa","volume":"17","author":"Kim","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ibrahim, A., Ahmed, M., Conway, R., and Carey, J.J. (2019). Risk of infection with methotrexate therapy in inflammatory diseases: A systematic review and meta-analysis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010015"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/acr2.11654","article-title":"Risk of Coccidioidomycosis Infection Among Individuals Using Biologic Response Modifiers, Corticosteroids, and Oral Small Molecules","volume":"6","author":"Wilson","year":"2024","journal-title":"ACR Open Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ijd.17501","article-title":"Infection risk with JAK inhibitors in dermatoses: A meta-analysis","volume":"64","author":"Ireland","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40257-022-00686-z","article-title":"Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature","volume":"23","author":"Ghanian","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaad.2024.02.045","article-title":"Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016\u20132022","volume":"91","author":"Bahr","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"adv43685","DOI":"10.2340\/actadv.v105.43685","article-title":"Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors","volume":"105","author":"Schwarz","year":"2025","journal-title":"Acta Derm. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaad.2024.09.037","article-title":"Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study","volume":"92","author":"Minami","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jcp.22331","article-title":"Reciprocal modulation between TH17 and other helper T cell lineages","volume":"226","author":"Bi","year":"2011","journal-title":"J. Cell Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12948","DOI":"10.1111\/pim.12948","article-title":"New insights into immunity to skin fungi shape our understanding of health and disease","volume":"45","author":"Ruchti","year":"2023","journal-title":"Parasite Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhou, S., and Yao, Z. (2022). Roles of Infection in Psoriasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136955"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40272-023-00611-9","article-title":"Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis","volume":"26","author":"Paller","year":"2024","journal-title":"Pediatr. Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaci.2023.05.025","article-title":"IL-4 receptor alpha blockade dampens allergic inflammation and upregulates IL-17A expression to promote S aureus clearance in antigen sensitized mouse skin","volume":"152","author":"McGurk","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1189\/jlb.0412214","article-title":"Regulation of inflammation by interleukin-4: A review of \u201calternatives\u201d","volume":"92","author":"Luzina","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","article-title":"The differential expression of IL-4 and IL-13 and its impact on type-2 immunity","volume":"75","author":"Bao","year":"2015","journal-title":"Cytokine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e74690","DOI":"10.7554\/eLife.74690","article-title":"Macrophage innate training induced by IL-4 and IL-13 activation enhances OXPHOS driven anti-mycobacterial responses","volume":"11","author":"Lundahl","year":"2022","journal-title":"eLife"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cytogfr.2014.07.010","article-title":"IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants","volume":"25","author":"Ranasinghe","year":"2014","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101520","DOI":"10.1016\/j.smim.2021.101520","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","volume":"58","author":"Bridgewood","year":"2021","journal-title":"Semin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis","volume":"136","author":"Yiu","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.S., Zeng, J., Mei, J., and Wang, P.Y. (2023). JAK\/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1110765"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Howard, F.H.N., Kwan, A., Winder, N., Mughal, A., Collado-Rojas, C., and Muthana, M. (2022). Understanding Immune Responses to Viruses\u2014Do Underlying Th1\/Th2 Cell Biases Predict Outcome?. Viruses, 14.","DOI":"10.3390\/v14071493"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.jahd.2024.100001","article-title":"Not just another klass (JAK) of inhibitors for allergies","volume":"1","author":"Brooks","year":"2024","journal-title":"J. Allergy Hypersensit. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12325-022-02322-y","article-title":"No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kridin, K., Abdelghaffar, M., Bieber, K., Thaci, D., and Ludwig, R.J. (2025). The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.20724"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/bjd\/ljaf032","article-title":"Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: Long-term results from the BE RADIANT phase IIIb trial open-label extension period","volume":"193","author":"Warren","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_34","unstructured":"Sanofi-Aventis US LLC (2025, September 01). DUPIXENT\u00ae (Dupilumab) Injection, for Subcutaneous Use. 2025, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761055s070lbl.pdf."},{"key":"ref_35","unstructured":"AbbVie (2025, September 01). SKYRIZI\u00ae (Risankizumab-Rzaa) Injection, for Subcutaneous or Intravenous Use. 2024, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761105s039,761262s011lbl.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1016\/j.vaccine.2023.05.052","article-title":"Immunogenicity, efficacy, and safety of CoronaVac and Pfizer\/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study","volume":"41","author":"Ergun","year":"2023","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_38","unstructured":"Pfizer Laboratories Div Pfizer Inc (2025, September 01). XELJANZ (Tofacitinib) Tablets, for Oral Use; XELJANZ XR (Tofacitinib) Extended-Release Tablets, for Oral Use; XELJANZ (Tofacitinib) Oral Solution. 2025, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203214s026lbl.pdf."},{"key":"ref_39","unstructured":"Pfizer Labs (2025, September 01). LITFULOTM (Ritlecitinib) Capsules, for Oral Use. 2023, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215830s000lbl.pdf."},{"key":"ref_40","unstructured":"FDA, CDER (2025, September 01). TREMFYA\u00ae (Guselkumab) Injection, for Subcutaneous or Intravenous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761061s026lbl.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1111\/jdv.19328","article-title":"Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors\u2014A population-based study","volume":"37","author":"Kridin","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/2053\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:50:24Z","timestamp":1763463024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/2053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61112053"],"URL":"https:\/\/doi.org\/10.3390\/medicina61112053","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}